Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Christine Hogan MD

Assistant Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Infectious Disease
Program: Administration


Publications (12)

  • The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. (Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S, A5217 Study Team) J Infect Dis 2012 Jan 01;205(1):87-96 PMID: 22180621 PMCID: PMC3242744 SCOPUS ID: 2-s2.0-84555189233 12/20/2011       87 Citations
  • The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. (Markowitz M, Vaida F, Hare CB, Boden D, Mohri H, Hecht FM, Kalayjian RC, Conrad A, Mildvan D, Aberg J, Hogan C, Kilby JM, Balfour HH Jr, Schafer K, Richman D, Little S) J Infect Dis 2010 May 01;201(9):1298-302 PMID: 20235838 PMCID: PMC2851487 SCOPUS ID: 2-s2.0-77950936860 03/20/2010       29 Citations
  • Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217. (Messer K, Vaida F, Hogan C) Contemp Clin Trials 2006 Dec;27(6):506-17 PMID: 16962381 SCOPUS ID: 2-s2.0-33750289763 09/12/2006       2 Citations
  • Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. (Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz M) J Acquir Immune Defic Syndr 2006 Apr 01;41(4):439-46 PMID: 16652051 SCOPUS ID: 2-s2.0-33646812239 05/03/2006       157 Citations
  • Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. (Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M) J Virol 2004 Dec;78(24):14039-42 PMID: 15564511 PMCID: PMC533925 SCOPUS ID: 2-s2.0-10044280760 11/27/2004       71 Citations
  • Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. (Di Mascio M, Markowitz M, Louie M, Hurley A, Hogan C, Simon V, Follmann D, Ho DD, Perelson AS) J Virol 2004 Oct;78(19):10566-73 PMID: 15367623 PMCID: PMC516378 SCOPUS ID: 2-s2.0-4544262243 09/16/2004       34 Citations
  • Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. (Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M) J Exp Med 2004 Sep 20;200(6):761-70 PMID: 15365095 PMCID: PMC2211967 SCOPUS ID: 2-s2.0-4644289983 09/15/2004       878 Citations
  • Viral blip dynamics during highly active antiretroviral therapy. (Di Mascio M, Markowitz M, Louie M, Hogan C, Hurley A, Chung C, Ho DD, Perelson AS) J Virol 2003 Nov;77(22):12165-72 PMID: 14581553 PMCID: PMC253757 SCOPUS ID: 2-s2.0-0242300180 10/29/2003       69 Citations
  • Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. (Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N, Lamy P, Flaherty J, Coakley D, Di Mascio M, Perelson AS, Markowitz M) AIDS 2003 May 23;17(8):1151-6 PMID: 12819516 SCOPUS ID: 2-s2.0-0037530011 06/24/2003       78 Citations
  • Determining the relative efficacy of highly active antiretroviral therapy. (Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, Ruiz N, Brun S, Sun E, Perelson AS, Ho DD, Markowitz M) J Infect Dis 2003 Mar 15;187(6):896-900 PMID: 12660935 SCOPUS ID: 2-s2.0-0037444053 03/28/2003       79 Citations
  • Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. (Hogan CM, Hammer SM) Ann Intern Med 2001 May 15;134(10):978-96 PMID: 11352699 SCOPUS ID: 2-s2.0-0035873546 05/16/2001       114 Citations
  • Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. (Hogan CM, Hammer SM) Ann Intern Med 2001 May 01;134(9 Pt 1):761-76 PMID: 11329234 SCOPUS ID: 2-s2.0-0035339928 05/01/2001       101 Citations
  • Last update: 06/01/2017